Abstract:
Cardiac hypertrophy and associated heart fibrosis remain a major cause of death worldwide. Phytochemicals have gained attention as alternative therapeutics for managing cardiovascular diseases. These include the extract from the plant Terminalia arjuna which is a popular cardioprotectant and may prevent or slow progression of pathological hypertrophy to heart failure. Here, we investigated the mode of action of a principal bioactive T. arjuna compound, arjunolic acid (AA) in ameliorating hemodynamic load-induced cardiac fibrosis and identified its intracellular target. Our data revealed that AA significantly represses collagen expression and improves cardiac function during hypertrophy. We found that AA binds to and stabilizes the ligand binding domain of peroxisome proliferator-activated receptor alpha (PPARα) and increases its expression during cardiac hypertrophy. PPARα knockdown during AA treatment in hypertrophy samples, including angiotensinII treated adult cardiac fibroblasts and renal artery-ligated rat heart suggests that AAdriven cardioprotection primarily arises from PPARα agonism. Moreover, AA-induced PPARα upregulation leads to repression of TGF-β signaling, specifically by inhibiting TGF-β activated kinase1 (TAK1) phosphorylation. We observed that PPARα directly interacts with TAK1, predominantly via PPARα N-terminal transactivation domain (AF-1) thereby masking the TAK1 kinase domain. AA-induced PPARα-bound TAK1 level thereby shows inverse correlation with phosphorylation level of TAK1 and subsequent reduction in p38 MAPK and NFκBp65 activation, ultimately culminating in amelioration of excess collagen synthesis in cardiac hypertrophy. In conclusion, our findings unravel the mechanism of AA action in regressing hypertrophy associated cardiac fibrosis by assigning a role of AA as a PPARα agonist that inactivates non-canonical TGF-β signaling.
Increased hemodynamic load in heart leads to activation of renin-angiotensin system (RAS) resulting in heightened local concentration of angiotensinII (AngII) which has been established as a principal causal factor for cardiac hypertrophy and associated fibrosis (3, 4, 5) . Therefore, ameliorating AngII-induced cardiac fibrosis might be one of the possible measures for prevention of such disease progression with improved efficacy of cardiac performance. Phytomedicines have been greatly appreciated in recent times as promising candidates towards alternative therapeutic regime in several fibrotic diseases (6, 7) . Terminalia arjuna (arjuna), being considered as one of the most accepted beneficial plants from ancient times has also widely been known to have cardiotonic functions (8) . Preclinical studies with arjuna extracts as well as clinical trials in the form of combination therapy with standard drugs have shown to be protective in several models of cardiac ailments (9, 10) . Arjunolic acid (AA), a chiral triterpenoid is one of the principal bioactive components of arjuna extracts. Aqueous extract of arjuna bark containing AA, significantly inhibited isoprenaline-induced increase in oxidative stress and also prevented fibrosis without regression of hypertrophy or improvement of cardiac function (11) . Purified AA resulted in anti-oxidant, antiplatelet, anti-coagulant, anti-necrotic, antiapoptotic, free-radical-scavenging, antiinflammatory, hypolipidemic or hypotensive effects in various cardiac disease models (9, 10, 12, 13) . However, the precise molecular mechanism of cardioprotection by AA has still remained elusive. Further, pleiotropic effects of AA make it even harder to annotate specific molecular targets within the cellular milieu. Thus, the objective of our study was to look into the effect of AA which is purified and crystallized from ethyl acetate and methanol extracts of the corewood of arjuna plant (14) on cardiac hypertrophy associated fibrosis and seek out its plausible mechanism of action on fibrotic signaling through identification of its specific molecular target. Our study for the first time establishes PPARα as a molecular target of AA. It is a ligand-dependent transcription factor and the most abundant PPAR isoform in heart (15) . PPARα primarily acts as a modulator of energy metabolism but also acts as anti-inflammatory agent (16, 17) . Growing evidences have shown that PPARα activators are involved in integrating inflammatory and hypertrophic pathways thereby governing the pathological outcome of hypertrophy associated fibrosis (18, 19, 20) in hypertensive rats in vivo. Moreover, PPARα double knockout mice subjected to transverse aortic constriction (TAC) showed much heightened fibrotic and inflammatory gene expressions along with severely aggravated hemodynamic function compared to wild type mice that has undergone TAC (21) . During pressure overload hypertrophy, autocrine and paracrine actions of locally expressed AngII induce TGF-β signaling in cardiac fibroblasts (2, 3) . Upon ligand binding, TGF-β receptor II (TβRII) transphosphorylates TGF-β receptor I (TβRI). In the canonical branch, active TβRI phosphorylates ‗suppressor of mothers against decapentaplegic' (SMAD 2/3) which combines with co-SMADs (SMAD 4) for nuclear translocation. Active nuclear SMADs upregulate transcription of several genes involved in ECM synthesis (3, 22) . SMAD3-/-mice have shown reduced cardiac fibrosis after TAC (23) . Independent of the SMAD kinase activity, noncanonical pathway is principally governed by MAPKs and TAK1 is a principal MAP3K. Phosphorylation-dependent activation of TAK1 requires interaction of its kinase domain with C terminal of TAK1 binding protein (TAB1) (24, 25) .
Once activated, TAK1 phosphorylates inhibitor of kappab kinase beta (IKKβ) (but not IKKα); MKK4/7 and MKK3/6 which in turn phosphorylates NF-kB; JNK and p38 MAPK respectively (25, 26) . Ultimately, NF-κB and other transcription factors downstream of JNK and p38 MAPK are activated resulting in transcription of the target genes (27) . Importance of non-canonical branch via TAK1 has also been well documented in cardiac hypertrophy and fibrosis (28) . Dominant negative TAK1 has been found to inhibit TGF-β induced hypertrophic events in mouse cardiomyocytes and fibroblasts, including ECM production (29) . Inhibitory effect of PPAR activation upon TGF-β signaling has been extensively documented (30, 31, 32) . Our work thus aims to study the role of PPARα in AA-driven modulation of TGF-β axes during cardiac hypertrophy and associated fibrosis. This work identifies PPARα::TAK1 interaction as a causal factor preventing TAK1 phosphorylation and further analyzes the relative strength of different PPARα domains contributing towards inhibition of non-canonical TGF-β axes and regression of subsequent collagen synthesis during cardiac hypertrophy.
Results: Arjunolic acid (AA) regresses collagen expression and improves cardiac function during cardiac hypertrophy:
AngII treatment in cardiac fibroblasts in vitro ( Figure 1A ) and renal artery ligation in vivo ( Figure 1B ) confirmed significant increase in collagen-1 (col-1; 2.29±0.032 fold in vitro and 1.71±0.017 fold in vivo) and collagen-3 (col-3; 1.96±0.035 fold in vitro and 1.76±0.015 fold in vivo) gene expressions compared to respective DMSO treated control samples as revealed by RT-PCR analyses ( Figure 1A-B) . Hydroxyproline assay also showed significant upregulation in total secreted collagen content in the fibroblast culture supernatant in vitro (471.99±20.188 ng/ml vis-à-vis 220.57±10.289 ng/ml of culture supernatant; Figure 1C ) as well as significantly increased total left ventricular collagen content in vivo (446.63±12.808 μg/g vis-à-vis 214.91±18.828 μg/g of wet tissue; Figure  1D ) in hypertrophy samples compared to respective control samples in vitro and in vivo ( Figure 1C-D) . AA treatment in AngII pretreated cardiac fibroblasts ( Figure 1A ) and renal artery ligated rat heart ( Figure  1B ) showed significant downregulation of col-1 (2.51±0.025 fold in vitro and 2.20±0.022 fold in vivo) and col-3 (1.77±0.050 fold in vitro and 1.86±0.016 fold in vivo) gene expressions compared to respective DMSO treated hypertrophy samples in vitro and in vivo ( Figure 1A-B) . Hydroxyproline assay further revealed that AA treatment during hypertrophy leads to significant reduction in total secreted collagen content in fibroblast culture supernatant (301.49±22.191 ng/ml vis-à-vis 471.99±20.188 ng/ml of culture supernatant; Figure 1C ) as well as total left ventricular collagen content (315.57±28.761 μg/g vis-à-vis 446.63±12.808 μg/g of wet tissue; Figure 1D ) compared to respective hypertrophy samples in vitro and in vivo ( Figure 1C-D) . In vitro adult cardiac fibroblasts were also treated with equivalent amount of AA showing no significant difference in col-1 and col-3 gene expressions ( Figure 1A ) or total secreted collagen content in the culture supernatant ( Figure 1C ), compared to control fibroblasts treated with equivalent amount of DMSO.
Hypertrophy was confirmed in vivo by significantly increased heart weight (in mg) to body weight (in g) ratio (HW:BW; 1.71±0.091 fold; Figure 1E ), increased cardiomyocyte crosssectional area (CSA) (627.42±21.197 μm 2 vis-à-vis 379.48±10.606 μm 2 ; Figure 1F ) and increased expression of atrial natriuretic factor (anf) (3.27±0.019 fold), β-myosin heavy chain (β-mhc) (2.54±0.092 fold) and skeletal alpha actin (acta1) (1.89±0.024 fold) genes ( Figure 1G ) in ligated rats compared to sham operated control rat heart. AA-mediated regression of hypertrophy was confirmed by significantly reduced HW:BW ratio (1.28±0.067 fold; Figure 1E ), significantly decreased CSA (505.81±20.326 μm 2 vis-à-vis 627.42±21.197 μm 2 ; Figure 1F ) and significant downregulation in anf (1.69±0.009 fold), β-mhc (2.38±0.086 fold) and acta1 (1.57±0.017 fold) gene expressions ( Figure 1G ) in AA treated hypertrophy samples compared to renal artery ligated rat heart ( Figure 1E-G Figure 1H ). The viability measured was more than 90% after AA treatment in all hypertrophied fibroblasts as checked by cell viability assay (data not shown). Effective dose of AA for both in vitro and in vivo experiments were determined by maximal regression of collagen during hypertrophy via dose-dependent study (data not shown).
AA directly interacts with PPARα :
Fluorescence and circular dichorism (CD) titrations of AA with PPARα: Steady state fluorescence titrations of PPARα with increasing concentrations of AA showed no apparent shifts around 330 nm ( max ), indicative of unaltered tertiary architecture. However, the corresponding hypo-chromic shifts observed indicated binding of AA to PPARα (Figure 2A-i) .
The binding was also apparent when monitored through CD analyses where similar titrations induced marginal secondary structure perturbations (near 55 μM) in this predominantly α-helical protein. (Figure 2A-ii Figure 2B ). AA stabilizes tertiary and secondary architecture of PPARα:
Thermal melting studies: Stabilization of the tertiary and secondary architecture of PPARα by AA was assessed by monitoring changes in melting temperature (Tm) ( Figure 2C -i, ii). In fluorescence thermal shift (FTS) assays, PPARα, bound to AA showed higher Tm (59.5±0.5 °C) compared to PPARα alone (56.4±0.2 °C) ( Figure 2C-i) . Similar trend was observed through CD studies where changes in both θ 218 (alpha-helical content, Figure 2C -ii) and θ 222 (beta content, inset Figure 2C- All atomistic molecular dynamics (MD) simulations: Molecular dynamics simulation trajectories of both free and AA-bound PPARα were analyzed for changes in backbone RMSD, gyration radius (Rg), root mean square fluctuations in Cα atoms (RMSF) as well as protein-ligand H-bond network occupancy. In simulations of PPARα alone, projection of variations in backbone RMSD versus Rg showed dual distribution of species along both components ( Figure 2E-i) . The projections were however dominated by the species with high RMSD and Rg compared to initial model. However in presence of AA, only moderate variations were observed along both components ( Figure 2E -ii). This system showed single distribution with dominant population close to initial starting conformation (low RMSD and marginal variations in Rg). These variations were identically reflected in RMSF analysis of both systems ( Figure 2E-iii Figure 4A ). Hydroxyproline assay also revealed significant recovery of secreted collagen content in fibroblast culture supernatant (420.72±28.943 ng/ml vis-à-vis 296.84±20.981 ng/ml of culture supernatant; Figure 4B ) as well as total left ventricular collagen content (418.82±21.927 μg/g vis-à-vis 262.29±18.828 μg/g of wet tissue; Figure 4C ) during PPARα siRNA treatment in AA treated hypertrophied groups compared to respective AA treated hypertrophy samples in vitro and in vivo. Collagen volume fraction (%CVF) showed significant downregulation (1.82±0.153 fold) during AA treatment in hypertrophied heart compared to ligated heart tissue. PPARα knockdown in AA treated ligated rats showed significant increase in %CVF (1.57±0.133 fold) compared to AA treated in vivo hypertrophy samples ( Figure 4D Molecular docking study: For docking between PPARα and TAK1, the interfacial interacting residues between these two proteins were identified using CPORT to limit the plausible protein-protein docking landscape. Using HADDOCK for docking, 23 clusters of the 296 predicted structures were found that represented 70.4 % of the water-refined models. The best conformation in the top cluster according to best fit HADDOCK score revealed not only that PPARα and TAK1 extensively interact via inter-protein hydrogen bonds, but also gives an insight into the possible binding interface. The model with the best HADDOCK score revealed maximum contribution of N terminal transactivation domain (AF-1) of PPARα for hydrogen bonding with TAK1 with added contribution of a few hydrogen bonds through the hinge region (H) and LBD. Only one residue at position 107 from DBD had been shown to interact with TAK1 ( Figure 7A ). Status of interaction between PPARα and TAK1 is summarized in Supplementary Table 2A 
Discussion:
Phytomedicines are promising candidates for unravelling novel strategies to combat maladaptive cardiac remodeling. The present study focuses on the precise mechanism of protection conferred by one such phytochemical arjunolic acid (AA) during pressure overload cardiac hypertrophy and fibrosis. Our investigation showed that AA significantly inhibits excess synthesis of collagen and its subsequent deposition in ECM during cardiac hypertrophy both in vitro and in vivo. Cardiac functional betterment was also observed with AA treatment in renal artery ligated rats along with significant regression of collagen synthesis and redemption from hypertrophic load ( Figure 1A -H, supplementary Figure S-1A-B) . This encouraged us to probe into the specific molecular mechanism involved in AA-mediated amelioration of fibrosis during cardiac hypertrophy. Arjunolic acid (2, 3, 23-trihydroxyolean-12-en-28-oic acid) is a pentacyclic triterpenoid moncarboxylic acid substituted by three hydroxy groups at position 2, 3 and 23 (CHEBI: 68381). Two hydroxyl groups and one hydroxymethyl group are attached to the -A‖ ring. The carboxyl group is attached at the ring junction of the cisfused -D‖ and -E‖ rings (35, 36) . Triterpenoids have long been known for their ability to suppress inflammatory pathways (37) and have been recognized to activate different PPARs (38, 39) . PPARα being the predominant cardiac isoform of PPAR family (15) , interaction of PPARα with AA was studied in detail. Stabilizing interaction between AA and PPARα was confirmed by fluorescence and CD titrations and thermal shift assays (Figure 2A, 2C) . FTIR spectrum of the conjugate in a cell free system also indicated successful docking via masking of the hydrogen bond forming groups of AA. However, amide-I and amide-A peaks of PPARα remained intact in the conjugate indicating maintenance of protein architecture ( Figure 2B ). Further evidences for AA as a potential agonist of PPARα came through molecular docking studies where the former occupied identical binding pocket as reported for established agonists such as Iloprost, TIPP-703 (40, 41) as well as fenofibrate (42) which is a well-known PPARα activator exerting its effect in ailment of cardiac fibrosis (18, 19) (Figure 2D ). Moreover, higher affinity of PPARα to AA compared to the other agonists as estimated by their free energy of binding suggests that AA might act as an even better agonist (Supplementary Table 1 ). Simulation outcomes further confirmed AAdriven stabilization of PPARα via persistence of strong hydrogen bonding network between AA and the LBD of PPARα ( Figure 2E ). In many previous reports, the agonistic potential had been attributed to stabilization of helices in this region (31, 43, 44) , which is also observed in our case through RMSF analysis ( Figure 2E-iii) . Altogether, these data suggested that AA-driven stabilization of PPARα could shift the equilibrium of PPARα toward the active configurations resulting in higher interactions with different co-regulators, thus augmenting activation of PPARα-driven transcriptional machinery (45, 46) . Presence of PPRE, the putative PPARα binding site on PPARα promoter suggests that PPARα might regulate its own transcription (47) . ChIP analyses coupled to qRT-PCR revealed AAinduced increased binding of PPARα upon PPRE within the PPARα promoter during hypertrophy and the resultant PPARα transcriptional activation increased PPARα mRNA and protein expression during AA treatment in hypertrophy in an autorgulatory loop ( Figure 3A-B JNK on the other hand showed no effect upon collagen synthesis at hypertrophic stimulus to cardiac fibroblasts in vitro ( Figure 6B ). Our group and also others have earlier shown the involvement of p38 MAPK (48, 49) and NFκBp65 (50, 51) in cardiac collagen biosynthesis. In addition to that, analysis of luciferase activity of col1a1 promoter containing NF-κBp65 binding site also revealed the role of NF-κBp65 as a transcriptional activator of collagen promoter during hypertrophy which could be targeted for inhibition by AA driven PPARα activation ( Figure 6C ). Interestingly, PPARα-mediated downregulation of non-canonical TGF-β axes during AA treatment in hypertrophy samples was associated with decreased phosphorylation of TAK1, without any alteration in its total level ( Figure 5A-B) . This clearly indicates that changes in TAK1 activation during AA treatment in hypertrophy samples results from post translational modifications and is not related to PPARα-mediated regulation of gene transcription. Reports stating PPARs' role in modulating signaling pathways by interacting with other signal intermediates (52, 53, 54) prompted us to check whether PPARα directly interacts with TAK1. Successful docking between PPARα and TAK1 as revealed by in silico analyses ( Figure  7A Figure 8B, Supplementary Figure S -5B). This finding also corroborates to inactivation of non-canonical branch of TGF-β signaling ( Figure 5A , 6A) during AA treatment in hypertrophy samples resulting from AA-induced PPARα upregulation ( Figure 3A -B) and increased interaction between PPARα and TAK1 ( Figure  7C ). Degree of regression of collagen synthesis as observed by overexpression of different PPARα domains into hypertrophied fibroblasts also followed the similar trend revealing maximum regression by ‗AF-1' overexpression ( Figure 8C ). An earlier report suggested that deletion of AF-1 region of PPARα did not affect its function keeping its DNA binding activity unaltered (55) . However, our study shows that ‗AF-1' region of PPARα promotes PPARα::TAK1 protein-protein interaction resulting in suppression of noncanonical TGF-β pathway and reduced collagen gene transcription during cardiac hypertrophy. H region (Helix-1) of PPAR-γ has been reported to bind with cytosolic kinases such as ERK5 (52) and PKC-α (53) in other cell types. Although significantly lower than ‗AF-1', interaction of ‗H+LBD' of PPARα with TAK1 also had a significant role in regression of non-canonical TGF-β pathway induced collagen synthesis during hypertrophy. In summary, our work for the first time shows a precise mechanism of arjunolic acid (AA) action in regression of cardiac hypertrophy associated fibrosis and subsequent betterment of cardiac function. This work assigns a new role of AA as a PPARα agonist and such transcriptional activation and increased expression of PPARα during aforesaid pathophysiological condition inactivates the non-canonical TGF-β axes ( Figure  9A ). Specific molecular mechanism involves direct interaction of PPARα, predominantly by its N terminal ‗AF-1' domain with TAK-1 kinase domain, leading to decreased phosphorylation of TAK1 and its downstream signal intermediates ultimately inhibiting excess collagen transcription during hypertrophy ( Figure 9B ). TGF-β signaling is one of the key mediators for maintenance of normal cellular function and homeostasis of cardiac fibroblasts (56) Adult cardiac fibroblast cells were isolated from 28-week-old male Wistar rat hearts by the collagenase dispersion method. Briefly, animals were euthanized in a prefilled Carbon dioxide (CO 2 ) chamber with 100% concentration of CO 2 , and the hearts were chopped and digested by collagenase (80 units/ml DMEM; Worthington). The cells were pelleted by centrifugation and resuspended in fresh complete DMEM supplemented with 10% fetal bovine serum and plated in cell culture flask. Cells were maintained at 37°C with 5% CO 2 and were subsequently passaged (49) . Generation of cardiac hypertrophy in vitro and in vivo: 75-80% confluent serum-starved adult cardiac fibroblasts were treated with 10 -8 mol/liter (Sar1)-Angiotensin II (AngII) (Bachem, Torrance, USA) for 24 hrs to generate cardiac hypertrophy model in vitro. AngII was replenished every 6 hrs throughout the incubation period (49) .
In vivo cardiac hypertrophy model was generated by ligating right renal artery of 28-week-old male Wistar rats (250-300 g) as described earlier (49) . Rats were anesthetized with an intraperitoneal (i.p) injection of a mixture of ketamine (80 mg/kg) and xylazine (12 mg/kg). Sham-operated control group underwent a similar procedure without renal artery ligation. Animals were maintained in optimum condition for 14 days and were sacrificed on the 15th day after surgery. Hearts were taken out, collected in liquid N 2 and stored in -80°C for future use. Hypertrophy was measured by the heart weight (HW in mg) to body weight (BW in g) ratio and activation of hypertrophy marker genes (anf, β-mhc and acta1) by RT-PCR anlyses (57) .
Measurement of cardiomyocyte cross-sectional area (CSA):
To analyse cardiomyocyte cross-sectional area as a marker of hypertrophy, hearts were excised, washed in 1X PBS, and fixed in Karnovsky's fixative. Then, samples were paraffin-embedded and cut into 4-5 μm sections. Tissue sections were processed and stained with hematoxylin and eosin (H&E) and cardiomyocyte cross sectional area in each sample was quantified (57) using a computer morphometric program (ImageJ, NIH).
Evaluation of collagen deposition:
Hydroxyproline Assay: Hydroxyproline assay was performed to measure total secreted collagen content in fibroblast culture supernatant in vitro and total left ventricular collagen content from rat heart tissues. With the help of standard curve, hydroxyproline content in the unknown samples were calculated. The amount of collagen was estimated by multiplying hydroxyproline content by a factor of 8.2 (49) .
Estimation of percentage of collagen volume fraction (%CVF):
Heart tissues from each group of animals were taken for the analysis %CVF. Coronal sections obtained from the equator of the left ventricle were fixed and stained with Massons' Trichrome (Sigma-Aldrich, St. Louis, MO) to analyse collagen deposition under microscope (Nikon NIS BR) (Nikon, Shinagawa, Tokyo, Japan) following standard protocol. Fifty sections were scanned and at least 10 images were captured from each section. Images were digitized and processed by ImageJ, a computer morphometric program. CVF was calculated as the sum of all collagen stained tissue areas of the coronal sections respresented as percentage (%) of the total surface of the section. Colour segmentation was applied to separate the stained tissues from other nonspecific objects (58) .
Determination of cardiac function:
Cardiac function of lightly sedated animals from sham operated control group, renal artery ligated group, AA treated hypertrophied rat group and PPARα siRNA infused AA treated ligated rat group were measured by M-mode echpcardiographic analysis by a transthoracic study in a short axis view at papillary muscle level on the 15th day before euthanization. In vivo ventricular PPARα siRNA injection was also guided by echocardiography. Digitized images were obtained using an ultrasound system (Vivid S5 system, GE Healthcare) for the calculation of fractional shortening (%FS); left ventricular internal diastolic dimension (LvIDd); left ventricular anterior wall diameter in diastole (LvAWDd); left ventricular anterior wall diameter in systole (LvAWDs); left ventricular posterior wall diameter in diastole (LvPWDd); left ventricular posterior wall diameter in systole (LvPWDs); end diastolic volume (EDV); end systolic volume (ESV); stroke volume (SV) and ejection fraction (EF) following standard guidelines (58) .
Treatment of fibroblasts with TGF-β:
Another set of adult cardiac fibroblasts were treated with active TGF-β-2 (Life Technologies, Waltham, MA) at a dose of 8 ng/ml of serum free media for 16 hrs as described previously (59) to induce hypertrophic effect. TGF-β treated cells were pretreated with AA with or without simultaneous treatment of PPARα siRNA following standard protocol.
Treatment with arjunolic acid (AA) in vitro and in vivo:
Arjunolic Acid (AA) was extracted and purified from core wood of the plant Terminalia arjuna (14) . In vitro hypertrophied fibroblasts were treated with 20 μM of AA (dissolved in DMSO) 6 hrs after first AngII treatment. Effective dose was chosen from a dose-dependent study (5 -100 μM of AA) based on optimal results with minimum mortality. A group of control fibroblasts were also treated with 20 μM of AA. All other control and AngII treated cells were also treated with equivalent amount of DMSO. Time-dependent changes upon AA treatment were analyzed in AngII treated cells at 3 hrs and 6 hrs after induction with AA. A set of TGF-β treated cells were also treated with 20uM AA 6 hrs after TGF-β treatment. In vivo renal artery ligated rats were treated with AA, dissolved in DMSO by intraperitoneal injection on every alternate day from day 6 upto day 14 at a dose of 10 mg/kg/day after ligation. Effective dose was chosen after a dose-dependent study (5 mg to 50 mg/kg/day as described above) based on optimal results. Untreated sham operated rats and renal artery-ligated rats were also treated with equivalent amount of DMSO. Animals were sacrificed after 14 days. 
Structural modeling of PPARα and TAK1:
The amino acid sequence of Rattus norvegicus PPARα (P37230) and TAK1 (P0C8E4) were retrieved from the UniProtKB database (http://www.uniprot.org/). The retrieved amino acid sequence of PPARα and TAK1 were subjected to a protein-protein BLAST (BLASTp) search against the protein data bank (PDB) to identify a suitable template structure for comparative modeling. The 3D structure predictions of these two proteins were then performed using I-TASSER (60). For rat-PPARα, PDB ID: 4BCR_A was selected as the best suited template with 99% identity and 45% sequence coverage (E-value 0.0). For rat-TAK1, PDB ID: 5JGA_A was selected as a suitable template with 93% identity and 58% sequence coverage (E value 5e -170 ). The best I-TASSER outputs were refined using ModRefiner (61) . The I-TASSER Z-scores were analysed to check the likelihood that the domains had correct folds and correct overall tertiary structure. The final model was also checked for its quality using ProQ2 (62) . Further, refined structures were subjected for MD simulation.
All atomistic molecular dynamics (MD) simulation:
To check for conformational stability, MD simulation was done using GROMACS 4.6.1 (63) . All atomistic simulations were carried out using the CHARMM36 all-atom force field (November release) (64, 65, 66) using periodic boundary condition. The starting model was solvated in a periodic box with TIP3 water model. 9 Na + ions were added to the solvent to neutralize electrical net charge of the protein. The system was then minimized for 50000 steps using a steepest decent algorithm with emtol of 200 kJ/mol after a minimization with emtol of 100 kJ/mol. This was followed by an equilibration run of 100ps in NVT ensemble with restrains on the protein atoms. The NPT ensemble was used for production simulation. Systems were simulated at 310K, maintained by a Berendsen thermostat with a time constant of 1 ps with the protein and nonprotein molecules coupled separately. Pressure coupling was done employing a parrinellorahman barostat using a 1 bar reference pressure and a time constant of 2.0 ps with compressibility of 4.5e -5 bar using isotropic scaling scheme. Electrostatic interactions were calculated using the Particle Mesh Ewald (PME) summation with 2 fs time step for each run. For simulations of PPARα::AA complex, identical parameters were employed. Topology for AA (PubChem ID: CID73641) and other parameters were assigned using SwissParam (67) .
Three dimensional structural modeling of the chemical compounds:
The 2D structures of AA (PubChem ID: CID73641), fenofibrate (PubChem ID: CID3339) were retrieved from the NCBI PubChem database. The compounds were drawn using ChemDraw 8 software. The two-dimensional molecules were then converted to threedimensional structures using OpenBabel (68). The energy minimization was performed using Maestro 9.8 (Schrӧdinger, LLC, New York).
Molecular docking: Docking of AA to PPARα was performed using the BSP-SLIM tool (69) . Briefly, the holostructures with similar global topology to PPARα were identified and geometric centers of bound ligands in the holo-forms were clustered to identify putative AA-binding sites. Subsequently, shape and chemical feature comparison of multiple target ligand conformers with all negative images of binding pockets was done employing the OMEGA program. Best overlay for each ligand conformer with the negative images was carried out using OEChem toolkit v.1.7 while the chemical features of AA were assigned using the Implicit-MillsDean color force field (70) . Finally, all ligand conformations were sorted by docking scores with a RMSD tolerance limit of 4 Å.
The top lowest energy binding complex was reranked by performing flexible docking using Molecular Operating Environment (MOE; v2009.10). The triangular matching placement method with the Affinity dG scoring function was employed to generate most favorable poses of ligand conformations by aligning ligand triplets of atoms with triplets of receptor site points. AA::PPARα Docking scores were compared to the score obtained for known agonists of PPARα i.e. Iloprost (PDB ID: 3SP6) and TIPP-703 (PDB ID: 2ZNN) and fenofibrate (Obtained through pre-docking by BSP-SLIM). On the other hand in silico binding affinities were calculated using AutoDock Vina 1.1.2 (71) extension of UCSF chimera (72) . For protein-protein docking, residues forming the interface surfaces were predicted. CPORT program drew a consensus for the interface residues using PIER, cons-PPISP, SPPIDER and PINUP. The consensus residues were mapped onto the model. The predicted interface residues were submitted to the PPARα and TAK1 monomer model for protein-protein docking to build the hetero-dimer model, using HADDOCK webserver (73, 74) . Molecular graphics and analyses were performed with the UCSF Chimera (72).
Fluorescence and circular dichorism (CD) spectroscopy:
Fluorometric titrations were carried out in LS55 Fluorescent spectrometer (PerkinElmer, Waltham, MA). At constant PPARα (in vitro translated and purified) protein concentration of 8 μM, titrations were carried with increasing concentrations of AA up to 100 μM with a prescan delay of 300 secs. Incubated samples were excited at 274 nm due to absence of tryptophan and emission spectra were recorded from 290 nm to 400 nm with excitation/emission slits set 10/10. CD titrations were carried out in J-1500 Circular Dichroism Spectrophotometer (Jasco, Easton, MD). Far UV CD titrations were carried out following similar protocol in a 2 mm path length quartz cuvette and scanned from 250-200 nm at scan rate of 200 nm per minute. Fluorescence-based thermal shift (FTS) assay: FTS assay for PPARα was done to assess tertiary structure stabilization by monitoring change in Tyr emission at 330 nm over the temperature range from 25 to 90 °C with step size of 2 °C.
Excitation and emission slits were kept at 5/10 with an equilibration time of 1 min at each step. Thermal denaturation of PPARα (8 μM) was done both in absence or presence of AA (100 μM). AA incubation with PPARα was done 30 mins prior to the experiment. To assess secondary structure stabilization of PPARα by AA, change in both ‗θ 218 ' and ‗θ 222 ' were monitored against temperature range of 25 to 90°C at ramping rate of 1°C per minute. In vitro coupled transcription-translation and in vitro interaction assay: Full length PPARα, cloned in pCDNA6/V5 His B mammalian expression plasmid (Invitrogen, Waltham, MA) was subjected to in vitro coupled transcription-translation using TNT® Quick coupled Transcription/Translation system (Promega, Madison, WI) according to the manufacturer's specifications. Briefly, 2 μg circular plasmids were added to the rabbit reticulocyte lysates in 50 μl reactions for 60-90 mins at 30 °C. These 6×His-tagged products were then purified using Ni-NTA spin kit (Qiagen, Hilden, Germany) in native condition and analyzed by SDS-poly-acrylamide gel electrophoresis (SDS-PAGE) followed by coomassie blue staining to check the purity (data not shown). Purified products were then subjected to in vitro interaction in binding buffer overnight on a rocker at 4 °C with AA (59) . This complex along with the purified protein was used for further assay. Fourier transform infra-red (FTIR) spectroscopy: FTIR spectra were obtained with a Jasco FTIR 6300 spectrometer (Jasco, Easton, MD). The spectra presented were obtained from an average of 64 scans. The resolution of the spectra was 4 cm -1 . The spectra were acquired at room temperature. All data analyses were performed with the data analysis software Origin (OriginLab, Northampton, MA) provided with the FTIR instrument.
RNA isolation:
Total RNA from cells (24 hrs treatment) and tissues (on the 15 th day after surgery) was isolated using TRIzol reagent (Invitrogen, Waltham, MA) following manufacturer's instructions.
RT-PCR and qRT-PCR:
1 µg of total RNA was used to make cDNA using the cloned avian myeloblastosis virus (AMV) first-strand cDNA synthesis kit (Invitrogen, Waltham, MA). RT-PCR was done for col-1, col- 
Chromatin immunoprecipitation (ChIP) assay:
ChIP analysis was performed with modifications from the methodology described by Kouskouti et al (75) . Briefly, cardiac fibroblasts and cardiac tissue sections were treated with 37% formaldehyde (final concentration 1%) for crosslinking proteins to DNA. Crosslinking was stopped by adding 10X Glycine (final concentration 0.125 M) after 10 mins and mixed at room temperature. Cardiac fibroblasts were now scraped out in ice cold 1X PBS with protease inhibitor cocktail (PIC) (#P8340; Sigma-Aldrich, St. Louis, MO). Cardiac tissue samples with crosslinked chromatin were also taken in ice cold 1X PBS with PIC and were thoroughly minced with Dounce homogenizer. Both in vitro and in vivo samples were now centrifuged at 1500 rpm for 5 mins at 4 °C and the pellet were resuspended in sonication buffer (50mM HEPES, 140 mM NaCl, 1 mM EDTA, 1% TritonX, 0.1% Sodium deoxycholate and 0.1% SDS; pH=7.9). The samples were now sonicated and centrifuged to obtain supernatants containing 500-800 bp sized chromatin fragments. For each reaction, 400 μg of purified chromatin was pre-cleared with protein G sepharose bead (#P3296; SigmaAldrich, St. Louis, MO) and immunoprecipitated overnight at 4 °C either by anti-PPARα antibody or anti-IgG antibody (used as a negative control) (antibodies listed in Supplementary Table 4) . Further, antibody-bound chromatin complexes were washed using low and high salt wash buffers followed by Tris-EDTA (TE) buffer wash, all at 4 °C. Protein-DNA complexes were eluted from beads by elution buffer (50 mM NaHCO 3 , 50 mM Tris, 1 mM EDTA and 1% SDS) for 10 mins at 65 °C. To separate protein from DNA, samples were treated with 21 μl of 4 M NaCl at 65 °C overnight. Further purification of DNA was done by RNase A (#R4875, SigmaAldrich, St. Louis, MO) incubation at 37 °C for 1 hr followed by addition of Proteinase K (#P6556, Sigma-Aldrich, St. Louis, MO), EDTA and Tris (pH 6.5) for 2 hrs at 42 °C. DNA extraction was done following phenol-chloroform isoamyl alchohol method and the purity and concentration was analyzed. 2 μl of DNA from each sample were used for ChIP coupled qRT-PCR (primers listed in Supplementary Table 3B Table 3C ) and cloned in frame into pCDNA6/V5 HisB mammalian expression vector (Invitrogen, Waltham, MA) with C-terminal His-Tag as described previously (59) . All the clones were confirmed by sequencing (Applied Biosystems TM , 3730 DNA Analyzer, Waltham, MA).
Plasmids were transfected to AngII treated adult cardiac fibroblasts with the help of TurboFect transfection reagent (Thermo Fisher Scientific, Waltham, MA) as per manufacturer's protocol. Empty pCDNA6/V5 His-B mammalian expression vector were also transfected into control and AngII treated cells. Dual luciferase assay: 2.4 kb collagen1a1-luc plasmid with insert sequence ranging between -2300 bp and 100 bp of collagen1a1 (col1a1) gene (UniProt # Q63121) with putative NF-κBp65 binding site was constructed in PGL-3 vector following standard protocol. Primers are listed in Supplementary  Table 3D . Clones were confirmed by sequencing (Applied Biosystems TM , 3730 DNA Analyzer) (Applied Biosystems, Waltham, MA). Col1a1-luc and pRL-TK (Promega, Madison, WI) were used for dual luciferase assay as per manufacturer's instruction. Birefly, luciferase activity of col1a1 promoter containing PGL-3 vector and Renilla luciferase activity of PRL-TK were measured in 20 μl of cell lysate using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) using a luminometer (Varioskan™ LUX multimode microplate reader, #VL0LA0D0, Thermo Fisher Scientific, Waltham, MA). Relative activity was defined as the ratio of firefly luciferase activity to Renilla luciferase activity (76) .
Protein isolation:
Protein from adult cardiac fibroblasts was isolated using M-PER ® mammalian protein extraction reagent (Thermo Fisher Scientific, Waltham, MA) according to manufacturer's protocol. Protein extracts were prepared from ventricular tissue following the procedure described previously (77) . Western Blotting: Western blot analyses were done to study protein expressions both in vitro and in vivo as described previously (77) . Briefly, 30 µg protein samples were separated in 10-12.5% SDS-PAGE and transferred to PVDF membrane. After blocking with 5% nonfat dry milk, membranes were incubated with polyclonal antibodies to TβRI, TβRII (Santacruz biotechnology, Dallas, Tx), total TAK1 (Abcam, Cambridge, UK), phospho (Thr 184/187) TAK1, phospho (Thr 180/Tyr182) and total p38 MAPK, total SMAD 3 and phospho (Thr 183/Tyr185) JNK (Cell signaling technology, Dannvers, MA) ; monoclonal antibodies to PPARα (Abcam, Cambridge, UK), phospho (Ser 465/467) and total SMAD 2, phospho (Ser 423/425) SMAD 3, phospho (Ser 536) and total NF-κBp65, total JNK, GAPDH (Cell signaling technology, Dannvers, MA), phospho (Tyr 199) and total IKKβ (Abcam, Cambridge, UK) and Horse radish peroxidase (HRP) conjugated secondary antibodies (Pierce, Waltham, MA). Specifications of the antibodies used are summarized in Supplementary Table 4 . Immunoreactive bands were visualized using Immobilon™ Western chemiluminescence HRP substrate (Millipore, Billerica, MA). List of antibodies are summarized in Supplementary  Table 4 . The blots were scanned and quantitated using GelDoc XR system and Quantity One® software version 4.6.3 (Bio-Rad, Hercules, CA).
Co-immunoprecipitation (Co-IP) assay:
Co-IP was done following manufacturer's protocol (Pierce Co-IP Kit, Thermo Fisher Scientific; Waltham, MA). Briefly, proteins were incubated with fast flow protein G or protein A sepharose beads and centrifuged to eliminate nonspecifically bound proteins (59) . 200 µg of precleared protein were immunoprecipitated using primary antibody. Immunoprotein complex was again incubated with protein G (#P3296, Sigma-Aldrich, St. Louis, MO) or protein A (#P3391; Sigma-Aldrich, St. Louis, MO) sepharose beads. Attached proteins were then eluted from beads in 1% SDS buffer followed by immunoblotting.
In this study, immunoprecipitation was done using primary antibodies for anti-PPARα or anti-His (antibodies are listed in Supplementary Table 4 ). For immunoprecipitation with anti-His, proteins were purified in nickel column, as described previously for in vitro protein purification above. Western blotting was done using monoclonal antibody against TAK1. Normalization was done by immunoblotting using the same antibodies used to immunoprecipitate the proteins.
Fluorescence recovery after photobleaching (FRAP):
For endogenous PPARα and TAK1 interaction, cells were treated with PPARα-TRITC and TAK1-FITC. As TRITC and FITC work as a donor-acceptor in FRAP assay, TRITC was subjected to 50% bleaching and FITC intensity in a single cell was measured. Fluorescence resonance energy transfer (FRET) efficiency was calculated in confocal microscope (Olympus FV1200, Olympus, Singapore) (76).
Statistical analysis:
All the results were expressed as mean ±S.E. of three independent experiments. Data were analyzed by independent sample t-test by SPSS (Version 14.0). For multiple comparison experiments, one way analysis of variance (ANOVA) was conducted followed by Tukey's post-hoc test. Results with p value <0.05 were considered significant. AngII treated cells were also treated with equivalent amount of DMSO. n=10 for each experimental group. Results were expressed as ±S.E. of three independent experiments. *, p<0.05 with respect to control cells; #, p<0.05 with respect to Ang II treated cells. D. Graphical representation of in vivo hydroxyproline assay showing significantly increased total left ventricular collagen content in ligated rat hearts compared to sham operated control hearts. AA treatment in ligated rat hearts showed decreased total left ventricular collagen content compared to ligated rat heart. Equivalent amount of DMSO were administered into sham operated and renal artery ligated rat group. n=7 for each experimental group. Results were expressed as ±S.E. of three independent experiments. **, p<0.01 with respect to sham operated control rat group; #, p<0.05 with respect to renal artery ligated rat group. E. Graphical representation of heart (HW/BW in mg/g) ratio showing significant increase in renal artery ligated rat group compared to sham operated control rat group. AA treatment in ligated animals showed significant downregulation of HW/BW ratio compared to hypertrophied rat group. Sham operated and renal artery ligated rat group were also treated with equivalent amount of DMSO. n=7 for each experimental group. Results were expressed as ±S.E. of three independent experiments. **, p<0.01 with respect to sham operated control rat group; ##, p<0.01 with respect to renal artery ligated rat group. F. Graphical representation of CSA measured from H&E stained heart tissue sections showing significant upregulation in renal artery ligated rat heart compared to sham operated control rat group. AA treatment in ligated animals showed significant downregulation of CSA compared to ligated rat group. Sham operated and ligated rats were also treated with equivalent amount DMSO. n=7 for each experimental group. Results were expressed as ±S.E. of three independent experiments. ***, p<0.001 with respect to sham operated control rat group; ###, p<0.001 with respect to renal artery ligated rat group. G. RT-PCR analyses showing significant increase in hypertrophy marker gene expressions namely anf, β-mhc and acta1 in renal artery ligated rat hearts compared to sham operated control hearts. AA treatment in ligated animals showed significant downregulation of all these gene expressions compared to ligated rat hearts. Sham operated control and renal artery ligated animals were also treated with equivalent amount of DMSO. Rpl-32 was used as internal loading control. n=7 for each experimental group. Results were expressed as ±S.E. of three independent experiments. Representative graphs showing relative alterations in the hypertrophy marker gene expressions among different experimental groups. ***, p<0.001 with respect to sham operated control rat group; **, p<0.01 with respect to sham operated control rat group; ###, p<0.001 with respect to renal artery ligated rat group; ##, p<0.01 with respect to renal artery ligated rat group. H. M-mode echocardiographic analyses from parasternal long axis view at papillary muscle level graphically representing decreased %FS and increased LvIDd in renal artery ligated rat group compared to sham operated control rat group. AA treatment in ligated animals showed restored %FS and lowered LvIDd in ligated rats compared to the hypertrophied rat group. Sham operated control and renal artery ligated animals were also treated with equivalent amount of DMSO. n=7 for each experimental group. Results were expressed as ±S.E. of three independent experiments. **; p<0.01 with respect to sham operated control rat group, ##; p<0.01 with respect to renal artery ligated rat group; #; p<0.05 with respect to renal artery ligated rat group. A. ChIP assay with anti-PPARα antibody followed by qRT-PCR analyses of the PPRE showing relative binding of PPARα to the PPRE within PPARα promoter among different experimental groups both in vitro and in vivo are represented graphically on logarithmic scale. Hypertrophy samples showed significantly downregulated fold enrichment in binding of PPARα to PPRE within PPARα promoter compared to respective controls. AA treatment in hypertrophy samples further showed significantly increased fold enrichment of the same, compared to hypertrophy samples. PPARα siRNA treatment in AA treated hypertrophy groups showing downregulated fold enrichment in binding of PPARα to the PPRE compared to AA treated hypertrophy samples were used as negative controls. Control and hypertrophy samples in vitro and in vivo were treated with equivalent amount of DMSO and Non-Specific (NS) siRNA. AA treated hypertrophy samples were treated with equivalent amount of NS siRNA. Chromatin from each experimental group immunoprecipitated with anti-IgG antibody were used for normalization. n=3 both in vitro and in vivo. Results were analyzed by one way analysis of variance (ANOVA) followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. **, p<0.01 with respect to control samples; ###, p<0.001 with respect to hypertrophy samples; ϮϮ, p<0.01 with respect to AA treated hypertrophy samples in vitro and/or in vivo. Corresponding changes in pparα mRNA expressions between different experimental groups as observed by qRT-PCR are represented graphically on logarithmic scale. Rpl-32 was used as internal loading control. n=3 both in vitro and in vivo. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. **, p<0.01 with respect to control samples; #, p<0.05 with respect to hypertrophy samples; ##, p<0.01 with respect to hypertrophy samples; Ϯ, p<0.05 with respect to AA treated hypertrophy samples; ϮϮ, p<0.01 with respect to AA treated hypertrophy samples in vitro and/or in vivo. B. Western blot analyses revealed significant decrease in PPARα protein expression during hypertrophy compared to respective control groups that again showed significant recovery in AA treated hypertrophy samples compared to respective hypertrophy groups in vitro and in vivo. Successful knockdown of PPARα protein expression was also confirmed by PPARα siRNA pretreatment in AA treated hypertrophy samples. GAPDH was used as internal loading control. Control and hypertrophy samples were treated with equivalent amounts of DMSO and NS siRNA. AA treated hypertrophy samples were also treated with NS siRNA. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. n=10 in vitro, n=7 in vivo for each experimental group. Representative graphs showing relative changes in expression of PPARα among different experimental groups on logarithmic scale. **, p<0.01 with respect to control samples; #, p<0.05 with respect to hypertrophy samples; ##, p<0.01 with respect to hypertrophy samples; ϮϮ, p<0.01 with respect to AA treated hypertrophy samples in vitro and/or in vivo. C. Western blot analyses showing time dependent increase in PPARα expression in AA treated hypertrophied fibroblasts compared to AngII treated cells at respective time points under study. GAPDH was used as internal loading control. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. n=5 for each experimental group. Representative graphs showing relative changes in PPARα expressions at respective time points among different groups under study. C, control fibroblasts; A, AngII treated fibroblasts at different time points; A+AA, AngII treated fibroblasts at different timepoints, treated along with AA. C and A cells were also treated with equivalent concentration of DMSO. ÞÞ<0.01 with respect to -A‖ samples at 3hr time point; øø<0.01 with respect to -A+AA‖ samples at 3hr time point. A. Graphical representation of qRT-PCR data showing significant downregulation of col-1 and col-3 gene expressions in AA treated hypertrophy samples compared to hypertrophy groups. PPARα siRNA pretreated hypertrophied groups treated along with AA showed significant recovery in these gene expressions compared to AA treated hypertrophy samples both in vitro and in vivo. Control and hypertrophy samples were treated with equivalent amount of DMSO and NS siRNA. AA treated hypertrophy samples were also treated with equivalent amount of NS siRNA. Rpl-32 was used as internal reference control. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. n=10 in vitro, n=7 in vivo for each experimental group. **, p<0.01 with respect to control samples; ***, p<0.001 with respect to control samples; ##, p<0.01 with respect to hypertrophy samples; Ϯ, p<0.05 with respect to AA treated hypertrophy samples; ϮϮϮ, p<0.001 with respect to AA treated hypertrophy samples in vitro and/or in vivo. B. Graphical representation of in vitro hydroxyproline assay showing significantly restored collagen content in the culture supernatant of PPARα siRNA pretreated hypertrophied fibroblasts treated along with AA compared to AA treated hypertrophied cells in vitro. Control and AngII treated cells were treated with equivalent amount of DMSO and NS siRNA. AA treated hypertrophied cells were also treated with equivalent amount of NS siRNA. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. n=10 for each experimental group. **, p<0.01 with respect to control cells; #, p<0.05 with respect to AngII treated cells; Ϯ, p<0.05 with respect to AngII treated cells treated along with AA. C. Graphical representation of in vivo hydroxyproline assay showing significant recovery in total left ventricular collagen content in PPARα siRNA pretreated AA infused hypertrophied heart compared to AA treated renal artery ligated rat heart in vivo. Sham operated control rats and renal artery ligated rats were also treated with equivalent amount of DMSO and NS siRNA. AA treated ligated rats were also treated with equivalent amount of NS siRNA. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. n=7 for each experimental group. **, p<0.01 with respect to sham operated control rat group; ##, p<0.01 with respect to renal artery ligated rat group; Ϯ, p<0.05 with respect to AA treated renal artery ligated rat group. D. Micrographs of Massons' Trichrome staining showing significantly decreased %CVF in AA-treated hypertrophy samples compared to renal artery ligated rat heart, which again showed significant recovery in AA treated ligated samples pretreated with PPAR siRNA. S; Sham operated control group, L; Ligated rat group, L+AA; AA treated Ligated rat group, L+AA+PPARα si; PPARα siRNA infused AA treated ligated rat group. S and L groups were treated with equivalent amount of DMSO and NS siRNA. L+AA group animals were also treated with equivalent amount of NS siRNA. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. n=7 for each group. (Scale Bar=40uM, Magnification=60X). **, p<0.01 with respect to sham operated control samples; ## , p<0.01 with respect to renal artery ligated hypertrophy samples; ϮϮ, p<0.01 with respect to renal artery ligated samples treated with AA. E. M-mode echocardiographic analyses of PPARα siRNA pretreated ligated rats treated with AA showing significant decrease in %FS and significant increase in LvIDd compared to AA treated ligated rats. Sham controls and renal artery ligated rats were treated with equivalent amount of DMSO and NS siRNA. AA treated ligated rats were also treated with equivalent amount of NS siRNA. n=7 for each group. Results were analyzed by ANOVA followed by Tukey's post-hoc test and expressed as ±S.E. of three independent experiments. **, p<0.01 with respect to sham operated control rat group; ##, p<0.01 with respect to renal artery ligated rat group; ϮϮ, p<0.01 with respect to AA treated renal artery ligated rat group. Figure 5 : AA-mediated upregulation of PPARα specifically targets TAK1 for regression of TGF-β signaling during cardiac hypertrophy: A. Western blot analyses showing significantly reduced TβRI, TβRII, phospho/total levels of SMAD 2, SMAD 3 and TAK1 in AA treated hypertrophy samples compared to hypertrophy groups both in vitro and in vivo. Significantly restored levels of all these proteins were observed in AA treated hypertrophy groups pretreated with PPARα siRNA compared to AA treated hypertrophy samples. Control and hypertrophy samples were treated with equivalent amount of DMSO and NS siRNA. AA treated hypertrophy samples were also treated with equivalent amount of NS siRNA. GAPDH was used as internal loading control. n=10 in vitro, n=7 in vivo for each experimental group. B. Western blot analyses showing significantly decreased phospho/total TAK1 level during AA treatment in TGF-β treated cardiac fibroblasts compared to only TGF-β treated cells. PPARα knockdown in TGF-β and AA infused cells showed significant recovery in phospho/total TAK1 level compared to AA treated fibroblasts pretreated with TGF-β. Expressions of TβRI, TβRII and phospho/total levels of SMAD 2 and SMAD 3 remained unaltered in these experimental groups. Control and TGF-β treated fibroblasts by guest on September 6, 2017 
